HSBC Saudi Arabia, the financial advisor, bookrunner, underwriter and lead manager on the initial public offering (IPO) of ...

Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares ...

The stock, now known as Meta Platforms, launched its IPO on May 18, 2012, when the Facebook parent introduced it at a price of $38 per share. At that time, $1,000 would have bought 26 shares, leaving ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

R.F. Lafferty & Co., Inc. acted as the representative of the underwriters, with Revere Securities LLC acting as co-underwriter (collectively, the “Underwriters”) for the Offering. The Crone Law Group, ...

The company launched the IPO after doubling revenue in 2024, driven by increased oil production from well acquisitions worth ...

Beta Bionics announced today that it went public after pricing a significantly upsized initial public offering (IPO).

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Beta Bionics (BBNX), a developer of insulin delivery devices, has set terms for an upsized $165M initial public offering.

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Beta Bionics has announced the pricing of its upsized initial public offering of 12 million shares of common stock at a price to the public of $17 per share.